Acute myeloid leukemia
Conditions
Interventions
Group 1:Consolidation therapy after remission adopts CLAG regimen
Group 2:Consolidation therapy after remission adopts high-dose cytarabine regimen
Sponsors
First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 60 years old; 2) AML patients who have been clearly diagnosed to meet the AML Chinese Guidelines 2017 edition standards; 3) Receive treatment in our hospital; 4) ECOG PS score: 0 2 points; 5) Normal function of main organs: serum bilirubin <=1.5 ULN, serum ALT and AST<=2.5 ULN, serum Cr<=1.5 ULN.
Exclusion criteria
Exclusion criteria: 1) The bone marrow cannot be sucked by puncture; 2) Relapsed AML; 3) Received treatment with Cladribine at any time; 4) Diagnosed with other malignant tumors within the previous 12 months; 5) Women who are pregnant or breastfeeding; 6) Uncontrollable systemic fungal, bacterial or viral infections (defined as the symptoms / signs associated with the infection at the time, but no improvement despite antibiotics or other treatments) 7) Known or suspected allergy to Cladribine; 8) Known active viral infection of human immunodeficiency virus (HIV) or viral hepatitis B or C; 9) Have a clear history of neurological or mental disorders, including epilepsy or dementia; 10) According to the judgment of the investigator, there are accompanying diseases that seriously endanger the safety of the patient or affect the completion of the study; 11) At the same time using other test drugs or participating in clinical trials of other drugs one month before the test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRD to negative rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year progression-free survival rate;2-year overall survival rate; | — |
Countries
China
Contacts
Public ContactYanfang Liu
First Affiliated Hospital of Zhengzhou University
Outcome results
None listed